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Background: Cationic solid lipid nanoparticles (SLNs) have been given considerable attention 
for therapeutic nucleic acid delivery owing to their advantages over viral and other nanoparticle 
delivery systems. However, poor delivery efficiency and complex formulations hinder the 
clinical translation of SLNs.
Aim: The aim of this study was to formulate and characterize SLNs incorporating the cholesterol 
derivative cholesteryl oleate to produce SLN–nucleic acid complexes with reduced cytotoxicity 
and more efficient cellular uptake.
Methods: Five cholesteryl oleate-containing formulations were prepared. Laser diffraction 
and laser Doppler microelectrophoresis were used to evaluate particle size and zeta potential, 
respectively. Nanoparticle morphology was analyzed using electron microscopy. Cytotoxicity 
and cellular uptake of lipoplexes were evaluated using flow cytometry and fluorescence 
microscopy. The gene inhibition capacity of the lipoplexes was assessed using siRNAs to block 
constitutive luciferase expression.
Results: We obtained nanoparticles with a mean diameter of approximately 150–200 nm in size 
and zeta potential values of 25–40 mV. SLN formulations with intermediate concentrations of 
cholesteryl oleate exhibited good stability and spherical structures with no aggregation. No cell 
toxicity of any reference SLN was observed. Finally, cellular uptake experiments with DNA- 
and RNA-SLNs were performed to select one reference with superior transient transfection 
efficiency that significantly decreased gene activity upon siRNA complexation.
Conclusion: The results indicate that cholesteryl oleate-loaded SLNs are a safe and effective 
platform for nonviral nucleic acid delivery.
Keywords: cationic solid lipid nanoparticles, SLNs, cholesteryl oleate, plasmid DNA, siRNA, 
transfection, cytotoxicity, uptake
Introduction
The development of efficient delivery systems is a critical factor for successful gene 
therapy.1 Numerous studies have described the use of vectors, such as retroviruses 
and adenoviruses, for delivering and expressing genes.2–4 While this approach often 
results in high expression efficiencies, it has several disadvantages, including marked 
immunogenicity, insertional mutagenesis, DNA package size limit, nonspecific 
effects, and potential hazards to laboratory personnel (comprehensive reviews are 
given in the studies by Collins and Thrasher,5 van der Loo and Wright,6 and Chira 
et al7). Alternatively, mechanical transfection methods, such as direct microinjection 
and the “gene gun,” or physical transfection methods, such as electroporation, sonopo-
ration, or laser irradiation, represent direct methods for delivering genetic material 
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into cells.8 Some of these methods have demonstrated their 
potential to directly transfer nucleic acids into cells and 
achieve good transgene expression. However, the instability 
of the nucleic acid and its rapid degradation, together with 
the associated toxicity, are still present.8 In recent decades, 
nanoparticle-mediated therapeutic nucleic acid delivery has 
been gaining considerable attention. Compared with viral 
systems, nanoparticles are less immunogenic and oncogenic 
and have no potential for virus recombination, all of which 
translates to improved safety.9 Nanoparticles are relatively 
easy to prepare and can incorporate nucleic acids with little 
toxicity.10 However, the transfection efficiency is low and a 
major concern in nanoparticle-mediated targeted therapy.11 
While considerable effort is needed to study the biological 
interactions of nanoparticles with cells and their constitu-
ent proteins,12 it has been widely observed that transfection 
efficiency is dependent on the specific properties of the 
nanoparticle, ie, its formulation.13 Nanoparticle diameter, 
shape, surface charge, and components influence cellular 
uptake and toxicity.14–17 Hence, the research and develop-
ment of novel nanoparticle formulations able to enter cells 
with high efficiency have been a priority for the clinical 
success of nanoparticle delivery systems.11,18
Depending on the manufacturing process and the physi-
cochemical properties, nanoparticles fall into different cat-
egories, ie, inorganic and organic nanoparticles. Among the 
first, a good example is gold nanoparticles, which can be used 
as cancer immunotherapy carriers or for diagnostic applica-
tions because they can be functionalized to detect low levels 
of specific targets.19–22 Organic nanoparticles have shown 
tremendous potential for broad clinical applications and gene 
therapy applications.23–25 As an example, several formula-
tions of polymeric nanoparticles containing poly(lactic-co-
glycolic acid) (PLGA), cyclodextrin, and chitosan have been 
developed for cancer therapy,26,27 and pH-sensitive polymers, 
which exhibit improved drug delivery to tumors, have shown 
increased antitumor activity with decreased side effects.28 
The fact that many nanoparticle-based approaches have been 
approved for clinical use serves as a proof of concept.29,30 
However, manufacturing processes, costs, toxicity, and 
transfection efficiency continue to hinder the widespread use 
of nanotechnology for clinical purposes in humans.1
Cationic solid lipid nanoparticles (SLNs) represent 
one of the most promising nanoparticle-based methods for 
gene therapy.31–35 SLNs were developed to overcome the 
limitations of polymeric nanoparticles and other lipid-based 
nanoparticles.36 They are based on the use of biocompatible 
lipids to produce a surface charge, which allows DNA and 
RNA binding and facilitates good biocompatibility and 
low cytotoxicity.10,37,38 SLNs are capable of transfecting 
nucleic acids into cells in vitro and in vivo,10,35 thus support-
ing their research and development for potential effective 
gene therapy strategies. SLNs can also be formulated for 
drug delivery and targeting through antibody-mediated, 
cationic lipid, and pH-sensitive lipid attachments.33 SLNs 
can be obtained using several methods with the advantage 
of avoiding organic solvent incorporation.39,40 Although 
SLNs have a remarkably wide range of properties and 
applications, they present some limitations and difficulties 
that need to be overcome before their translation into the 
clinic. Poor delivery efficiency, uncontrollable nanoparticle 
transport inside the body, and problems related to realizing 
some manufacturing processes at a large scale to meet Good 
Manufacturing Practice (GMP) standards are limitations that 
explain the small number of these products on the market.41 
Enhanced SLN formulations need to be engineered to over-
come these obstacles and produce effective nanoparticle 
systems for the successful intracellular delivery of nucleic 
acids and the improvement in nanomedicine development 
and translation.
The use of the cholesterol derivative cholesteryl oleate 
in SLN formulations has not been reported. In this study, we 
proposed the use of cholesteryl oleate to obtain an optimized 
formula that maintains the nanoparticle structure, morphol-
ogy, and nucleic acid binding efficiency while improving 
both cytotoxicity and transfection to induce potent biological 
activity. We used a simple fabrication method with inex-




The following materials were used to synthesize the nano-
particles: poloxamer 188 (Sigma-Aldrich Co., St Louis, MO, 
USA), octadecylamine (Acros Organics, Geel, Belgium), 
stearic acid (EMD Millipore, Billerica, MA, USA), choles-
teryl oleate (Alfa Aesar, Karlsruhe, Germany), and ultrapure 
water (EMD Millipore). The SLNs were produced using the 
hot microemulsification method, as previously described.42 
Briefly, all components were melted, and the matrix lipid 
was poured with stirring onto the cationic lipid, water, and 
surfactant solution to form a hot emulsion. The emulsion 
was dispersed into cooled water at 2°C–3°C (ratio 1:5) under 
stirring to form the SLNs. The final microemulsion was 
centrifuged at 15,000 rpm (approximately 19,000× g) and 
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Cholesteryl oleate in SLNs for enhanced therapeutic efficacy
their properties and to improve the stability. The amount of 
the matricial lipid (cholesteryl oleate + stearic acid) varied 
depending on the formulation (Table 1). All assays except 
for the electronic microscopy studies were performed with 
lyophilized SLNs (L-3 Telstar; Telstar, Terrassa, Spain) using 
trehalose (5% w/v) as a cryoprotectant.
Plasmid constructs and sirNas
The major histocompatibility complex (MHC) reporter 
luciferase plasmid has a minimal fos promoter element and 
three copies of the MHC class I κΒ element and has been previ-
ously described.43 The sequence of the Cy3-labeled siRNA was 
as follows: 5′-CUACAACAGCCACAACGE-3′ (siEGFP).44 
The sequence of the siRNA targeting luciferase (siLUC) was 
as follows: 5′-UUGUAUUCAGCCCAUAGC-3′.45
Determination of slN particle size
SLN suspensions were used for particle size determination by 
laser diffraction according to the Mie theory on a Mastersizer 
2000 (Malvern Instruments, Malvern, UK). All samples were 
measured in triplicate using a sufficient amount of sample 
to obtain an appropriate obscuration percentage. A Fourier 
transform was applied to the measured diffracted angles to 
obtain the particle size data using specialized software, and 
the mean value was calculated in nanometers.
Determination of SLN surface charge 
(zeta potential)
A Zetasizer Nano Z (Malvern Instruments) was used to 
determine the surface charge of the SLNs by laser Doppler 
microelectrophoresis. Samples were stabilized at 25°C prior 
to measurement. The electrophoretic mobility between 
electrodes connected to the cell containing the sample was 
converted to zeta potential values using specific software. 
Results are expressed in mV.
Morphological analysis of SLNs
The surface and content homogeneity of the SLNs were ana-
lyzed by transmission electron microscopy (TEM) using a Spirit 
120 kV microscope (FEI Company, Hillsboro, OR, USA).
cell culture and transfection assays
HEK293T cells were obtained from the American Type 
Culture Collection (ATCC, Manassas, VA, USA) and 
grown and maintained as previously described.46 For the 
viability assays, HEK293T cells were grown in 35 mm 
plates (Fisher Scientific, Madrid, Spain) to approximately 
60%–70% confluence. Because the concentration of octa-
decylamine varied according to the performance of the 
manufacturing process, we measured its concentration 
using a Varian 212 liquid chromatography mass spectrom-
etry (LC-MS) system, and the test volumes were selected 
based on the concentration of octadecylamine present in the 
samples to ensure that the amount of octadecylamine and the 
octadecylamine:cholesteryl oleate ratio remained constant. 
Accordingly, SLNs were added to the cell cultures using 
23.4 µL of reference 12, 14.2 µL of reference 13, 5 µL of 
reference 14, 4.25 µL of reference 15, and 11.6 µL of refer-
ence 16 (Table 1). After 24 and 48 h, cells were harvested 
and processed for cytotoxicity using flow cytometry analysis. 
For all the biological assays implicating nucleic acids, the 
complexes were prepared by mixing SLNs with the appro-
priate amount of plasmid DNA (pDNA) or siRNA as given 
in the following sections. The mixture was kept at room 
temperature for 40–45 min to allow the complexes to form 
before transfection. For the luciferase assays, HEK293T cells 
were grown in 35 mm plates to approximately 60%–70% 
confluence, and then the medium was changed to a medium 
without serum or antibiotics. Lipoplexes were prepared by 
mixing 1,000 ng of the MHC reporter luciferase plasmid, 100 
ng of Renilla plasmid, and the amounts of SLNs derived from 
the viability assay as mentioned earlier. The mixtures were 
added to the cells, and after 4–6 h, 200 µL of serum was added 
to each well. The cells were harvested approximately 48 h 
after transfection and processed for luciferase activity using 
the dual-luciferase reporter assay (Promega Corporation, 
Fitchburg, WI, USA) protocol following the manufacturer’s 
instructions. For the transfection of Cy3-labeled siRNA, 
HEK293T cells were grown in 35 mm plates (Falcon) to 
approximately 60%–70% confluence, and the medium was 
changed to a medium without serum or antibiotics. Lipo-
plexes were prepared by mixing 60 or 120 nM of Cy3-labeled 
siRNA and 13.5 µL of reference 14 SLNs. As a transfection 
control, 60 nM of Cy3-labeled siRNA was transfected into 
cells using Lipofectamine 2000 according to the manufac-
turer’s protocols. Then, the cells were transfected with the 
lipoplexes. Cells were harvested at different times after 
transfection and processed for flow cytometry and confocal 
microscopy analysis. For the transfection of siLUC, we used 
Table 1 Composition of the engineered nanoparticles
Components References
12 13 14 15 16
Stearic acid (mg) 400 300 200 100 0
Cholesteryl oleate (mg) 100 200 300 400 500
Octadecylamine (mg) 600 600 600 600 600




































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





Figure 1 Particle size distribution of reference 12 (A), reference 13 (B), reference 14 (C), reference 15 (D), and reference 16 (E) measured by laser diffraction.
Notes: Composition of the engineered nanoparticles – reference 12: 400 mg stearic acid, 100 mg cholesteryl oleate, 600 mg octadecylamine, 100 mg poloxamer 188; 
reference 13: 300 mg stearic acid, 200 mg cholesteryl oleate, 600 mg octadecylamine, 100 mg poloxamer 188; reference 14: 200 mg stearic acid, 300 mg cholesteryl oleate, 
600 mg octadecylamine, 100 mg poloxamer 188; reference 15: 100 mg stearic acid, 400 mg cholesteryl oleate, 600 mg octadecylamine, 100 mg poloxamer 188; reference 16: 
0 mg stearic acid, 500 mg cholesteryl oleate, 600 mg octadecylamine, 100 mg poloxamer 188.
Abbreviation: d, diameter.
Figure 2 TEM images of reference 12 (A), reference 13 (B), reference 14 (C), reference 15 (D), and reference 16 (E).
Notes: scale bars are in µm. Composition of the engineered nanoparticles – reference 12: 400 mg stearic acid, 100 mg cholesteryl oleate, 600 mg octadecylamine, 100 mg 
poloxamer 188; reference 13: 300 mg stearic acid, 200 mg cholesteryl oleate, 600 mg octadecylamine, 100 mg poloxamer 188; reference 14: 200 mg stearic acid, 300 mg 
cholesteryl oleate, 600 mg octadecylamine, 100 mg poloxamer 188; reference 15: 100 mg stearic acid, 400 mg cholesteryl oleate, 600 mg octadecylamine, 100 mg poloxamer 
188; reference 16: 0 mg stearic acid, 500 mg cholesteryl oleate, 600 mg octadecylamine, 100 mg poloxamer 188.
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Cholesteryl oleate in SLNs for enhanced therapeutic efficacy
the TZM-bl cell line. TZM-bl is a HeLa cell line that contains 
integrated copies of the luciferase and B-galactosidase genes 
under the control of the HIV-1 promoter (NIH AIDS Reagent 
Program, Germantown, MD, USA).47 Cells were grown in 
35 mm plates to approximately 60%–70% confluence, and 
the medium was changed to a medium without serum or 
antibiotics. Lipoplexes were prepared by mixing 120 nM of 
siLUC and different amounts of reference 14 SLNs. Cells 
were transfected with the lipoplex mixtures, and after 4–6 h, 
200 µL of serum was added to each well.
cell proliferation
Cell proliferation was detected using the MTT reagent 
(Hoffman-La Roche Ltd., Basel, Switzerland). Briefly, 10 µL 
Figure 3 (A) cell viability assays in heK293T cells with references 12–16 at 24 and 48 h. Data are from two independent experiments (mean ± seM). (B) MTT assay of 
HEK293T cells at different time points following treatment with reference 14. Data are from one representative experiment performed in quadruplicate.
Notes: Composition of the engineered nanoparticles – reference 12: 400 mg stearic acid, 100 mg cholesteryl oleate, 600 mg octadecylamine, 100 mg poloxamer 188; reference 
13: 300 mg stearic acid, 200 mg cholesteryl oleate, 600 mg octadecylamine, 100 mg poloxamer 188; reference 14: 200 mg stearic acid, 300 mg cholesteryl oleate, 600 mg 
octadecylamine, 100 mg poloxamer 188; reference 15: 100 mg stearic acid, 400 mg cholesteryl oleate, 600 mg octadecylamine, 100 mg poloxamer 188; reference 16: 0 mg stearic 
acid, 500 mg cholesteryl oleate, 600 mg octadecylamine, 100 mg poloxamer 188.
Abbreviations: ctrl, control; h2O2, hydrogen peroxide; SEM, standard error of the mean.
Figure 4 MHC (1000 ng) (A) and Renilla (100 ng) (B) plasmids were transfected into heK293T via slNs (references 12–16).
Notes: Data are from three independent experiments performed in triplicate (mean ± seM). ***P  0.001. MHC, plasmid containing a minimal fos promoter and three copies 
of the Mhc class I κΒ element. Composition of the engineered nanoparticles – reference 12: 400 mg stearic acid, 100 mg cholesteryl oleate, 600 mg octadecylamine, 100 
mg poloxamer 188; reference 13: 300 mg stearic acid, 200 mg cholesteryl oleate, 600 mg octadecylamine, 100 mg poloxamer 188; reference 14: 200 mg stearic acid, 300 mg 
cholesteryl oleate, 600 mg octadecylamine, 100 mg poloxamer 188; reference 15: 100 mg stearic acid, 400 mg cholesteryl oleate, 600 mg octadecylamine, 100 mg poloxamer 
188; reference 16: 0 mg stearic acid, 500 mg cholesteryl oleate, 600 mg octadecylamine, 100 mg poloxamer 188.
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of MTT was added to the plate and incubated for 4 h at 37°C. 
The purple precipitate of the cells was treated with solubili-
zation buffer, as indicated by the manufacturer, to dissolve 
the crystals. The absorbance at 570 nm was measured with 
an enzyme-linked immunosorbent assay (ELISA) reader 
(Molecular Devices LLC, Sunnyvale, CA, USA) at different 
time points after treatment.
Flow cytometry
Cytometry was performed on a FACSCalibur (BD Biosci-
ences, San Jose, CA, USA), and the results were analyzed 
using FlowJo software. The cutoff values were estab-
lished using unstained HEK293T cells to subtract the 
autofluorescence signal of the cells. At this setting, only 
0.5%–1% of the cells were over the 100 level for the Cy3 
fluorescence channel.
confocal microscopy
Confocal microscopy studies were performed using a Leica 
SP5 spectral confocal laser scanning microscope (Leica 
Microsystems, Wetzlar, Germany). Images were analyzed 
and digitally processed for presentation using LAS AF v2.3.6 
software (Leica Microsystems) and Adobe Photoshop CS3 
extended v10.0 software, respectively.
statistical analyses
Statistical analyses were performed using Graph Pad Prism 5.0 
(GraphPad Software, Inc., La Jolla, CA, USA) with one-way 
analysis of variance (ANOVA) followed by Tukey’s posttest 
analysis to describe significant differences between groups. 
The P-values are represented by asterisks (**P = 0.001–0.01 
and ***P  0.001). The absence of an asterisk indicates that the 
change relative to the control is not statistically significant.
Figure 6 Confocal microscopy images of HEK293T cells transfected with Cy3-labeled siRNA alone (A), together with Lipofectamine (B), or together with reference 14 (C) 
at 1 h post-transfection.
Notes: DAPI (4’,6-damidino-2-phenylindole) labeling was used to stain the chromatin (blue). Scale bars, 25 µm. Composition of reference 14: 200 mg stearic acid, 300 mg 
















































Figure 5 The cell transfection percentage (A) and the mean signal intensity (B) of complexes formed with 60 and 120 nM siegFPcy3 with reference 14 measured by 
flow cytometry.
Notes: Data are from two independent experiments (mean ± seM). *P = 0.01–0.05, **P = 0.001–0.01, and ***P  0.001. siEGFPCy3, small interfering RNA against the 
enhanced green fluorescent protein labeled with cyanine dye 3. Composition of reference 14: 200 mg stearic acid, 300 mg cholesteryl oleate, 600 mg octadecylamine, 100 mg 
poloxamer 188.
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Cholesteryl oleate in SLNs for enhanced therapeutic efficacy
Results
Preparation and characterization of slNs
The particle size results from the initial characterization of 
the different SLN references 12–16 are shown in Figure 1. 
We obtained an important population of particles approxi-
mately 150–200 nm in size, confirming the presence of 
nanoparticles. References 12–14 contained homogeneous 
material with almost no aggregates present (Figure 1A–C). 
We observed an increased amount of aggregation in refer-
ence 15, but nanoparticles were also synthesized (Figure 1D). 
Reference 16, which was synthesized with 100% cholesteryl 
oleate, contained numerous aggregates (Figure 1E). These 
results showed that references 12–14 were the best suitable 
to form lipoplexes for transfection purposes. Concerning 
zeta potential, there were no differences among the different 
formulations (Table 2). All the references had zeta potential 
values from 25 to 40 mV, which indicated a potentially good 
capacity for nucleic acid binding.
Images of the SLNs were acquired by TEM as shown 
in Figure 2. We observed the presence of nanostructures 
in all the formulations. However, the homogeneity and 
quality of these particles were substantially different in 
each formulation. For references 12–14, the images showed 
Figure 7 HEK293T cells were transfected with Cy3-labeled siRNA together with reference 14 and were analyzed at 1, 2, and 6 h after transfection using confocal microscopy 
(A and B).
Notes: Grayscale images are shown in part B. Scale bars, 25 μm. Composition of reference 14: 200 mg stearic acid, 300 mg cholesteryl oleate, 600 mg octadecylamine, 
100 mg poloxamer 188.
Figure 8 activity of silUc upon transfection via reference 14 slNs in TZM-bl cells.
Notes: Data are from five experiments performed in duplicate (mean ± seM). 
**P = 0.001–0.01 and ***P  0.001. Composition of reference 14: 200 mg stearic 
acid, 300 mg cholesteryl oleate, 600 mg octadecylamine, 100 mg poloxamer 188.
Abbreviations: SEM, standard error of the mean; siLUC, siRNA targeting 
luciferase; slNs, solid lipid nanoparticles.
Mock 9 10

























Table 2 slN zeta potentials






Notes: Composition of the engineered nanoparticles – reference 12: 400 mg stearic 
acid, 100 mg cholesteryl oleate, 600 mg octadecylamine, 100 mg poloxamer 188; 
reference 13: 300 mg stearic acid, 200 mg cholesteryl oleate, 600 mg octadecylamine, 
100 mg poloxamer 188; reference 14: 200 mg stearic acid, 300 mg cholesteryl oleate, 
600 mg octadecylamine, 100 mg poloxamer 188; reference 15: 100 mg stearic 
acid, 400 mg cholesteryl oleate, 600 mg octadecylamine, 100 mg poloxamer 188; 
reference 16: 0 mg stearic acid, 500 mg cholesteryl oleate, 600 mg octadecylamine, 
100 mg poloxamer 188.
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a high proportion of nanoparticles without any amorphous 
structures. In contrast, images of references 15 and 16 showed 
less spherical nanoparticles. In reference 16, we also observed 
many aggregates using a large field of view (data not shown). 
For reference 16, it was difficult to find images containing 
nanoparticles, further suggesting that the presence of 100% 
cholesteryl oleate in the formula yields nanoparticles that 
become unstable. These results are consistent with the laser 
diffraction data and confirm the suitability of references 
12–14 for further investigation.
cytotoxicity
An early and crucial stage in determining the efficacy of 
nanoparticles is toxicity testing. To determine the effect of the 
SLNs on cellular viability, a fixed quantity of nanoparticles 
from each reference was incubated with HEK293T cells 
for 48 h. We assessed cell viability by counting the number 
of viable cells using flow cytometry analysis. Variability in 
the nanoparticle concentration among the samples was mini-
mized by quantifying octadecylamine via LC-MS. No toxic 
effects of any SLN reference were observed (Figure 3A). 
Moreover, the viability of SLN-containing cells was similar 
to that of untreated cells after the incubation time (Figure 3A). 
These results show that the modified SLNs are not harmful 
to human cells cultured in vitro. The cytotoxicity against 
HEK293T cells was also studied using the MTT colorimetric 
cell proliferation assay. Time-dependent cytotoxic effects of 
SLNs from reference 14 (selected based on their physico-
chemical characteristics and good performance as given in 
the following sections) were observed as shown in Figure 3B. 
While initial cytotoxicity was observed at 24 h after treat-
ment, the cells recovered quickly and showed almost normal 
viability at later treatment time points (Figure 3B).
Cellular uptake and biological activity
The cellular uptake of nanoparticles and their capabil-
ity to generate a biological response can be tested by the 
luciferase reporter assay, where pDNA driving the expres-
sion of the luciferase gene is transfected into cells. Using 
this assay, we tested the cellular uptake and bioactivity 
of two different luciferase reporter plasmids (MHC and 
Renilla) using references 12–16 (Figure 4A and B) in the 
same quantities employed in the viability assays. While 
we observed a dose–response effect in the luciferase 
activity upon transfection with SLNs from references 12 
to 14, the enzymatic activity decreased upon transfection 
with SLNs from references 15 and 16. These results corre-
late with the physicochemical parameters of the SLNs and 
suggest that aggregation and poor stability are detrimental 
to transfection efficiency and bioactivity. Reference 14 
resulted in potent luciferase activity (Figure 4A and B), 
which is consistent with the previously determined size and 
morphology data of this formulation (our results) and with 
the binding capacity of these nanoparticles.10,42 We concluded 
that our cholesteryl oleate-based SLNs can be internalized 
in cells and generate a biological response. Therefore, these 
SLNs provided protection against nuclease activity, enabling 
cellular uptake, intracellular nucleic acid release and RNA 
transcription in the nucleus, transport to the cytoplasm, and 
translation into protein, enabling bioactivity. Reference 14 
showed good physicochemical parameters and superior 
transfection efficiency and was therefore suitable for further 
experimentation.
A more relevant model for RNA interference (RNAi) 
applications is the siRNA-mediated targeting of endog-
enous gene products rather than the transient transfection of 
plasmid-based genes. Therefore, we generated a synthetic 
siRNA against the luciferase gene to be used in subsequent 
experiments. First, we used flow cytometry to evaluate the 
cellular uptake of SLN-Cy3-labeled siRNA complexes 
using reference 14 in HEK293T cells. SLN complexation 
was performed with 60 and 120 nM Cy3-labeled siRNA. 
After the quantification analysis, the transfection efficiency 
of the SLN-Cy3-labeled siRNA complexes was approxi-
mately 40%–45% (Figure 5A). However, the SLNs elicited 
increased signal intensity compared with Lipofectamine 2000 
(Figure 5B). Interestingly, we observed an increase in signal 
intensity when using larger quantities of SLN-Cy3-labeled 
siRNA complexes (Figure 5B). Given that both siRNA con-
centrations exhibited similar transfection efficiency, these 
data suggest that more fluorescent siRNA is introduced into 
each individual cell, which may give rise to an increased 
biological response.
The transfection efficiency data were further supported 
by the confocal microscopy results. We observed a lack 
of fluorescence when the Cy3-labeled siRNA alone was 
added to the cells (Figure 6A). Many large fluorescent dots 
were observed in the cytoplasm and in the nucleus at 1 h 
post-transfection of the Cy3-labeled siRNA using Lipo-
fectamine 2000 (Figure 6B). Importantly, the addition of 
the SLN-Cy3-labeled siRNA complexes resulted in similar 
fluorescence signals (Figure 6C), reflecting the efficient cell 
binding and intracellular uptake of the lipoplexes. While 
strong fluorescence signals were still observed at 2 h post-
transfection, weak fluorescence was detected at 6 h post-
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Cholesteryl oleate in SLNs for enhanced therapeutic efficacy
or flow cytometry (data not shown), thus revealing the rapid 
intracellular uptake of these lipoplexes. Grayscale images 
(Figure 7B) showed multiple arrays of fluorescence signals 
widely spread throughout the cells, which may explain the 
loss of signal observed with image color information.
To confirm that the SLNs could deliver and release siRNA 
molecules into cells to result in bioactivity, we performed 
transfection experiments using TZM-bl cells, which carry 
integrated copies of the HIV-1 long terminal repeat driv-
ing expression of the luciferase gene. Targeting luciferase 
expression with SLN-siLUC complexes using different 
quantities of reference 14 resulted in an approximately 35% 
reduction in luciferase activity after 48 h compared with 
the control (Figure 8). This downregulation of endogenous 
luciferase expression validated the use of SLNs incorporat-
ing cholesteryl oleate in their formulation as promising tools 
for gene targeting.
Discussion
Identification of new formulations and cationic compounds 
for therapeutic use is of fundamental importance for achiev-
ing therapeutic nucleic acid transfer. This objective must 
be attained with consideration for the requirements of cost-
optimized large-scale production. The purpose of this study 
was to formulate and characterize SLNs incorporating the 
cholesterol derivative cholesteryl oleate to achieve SLN–
nucleic acid complexes with more efficient cellular uptake 
and reduced cytotoxicity. The steroid lipid cholesterol is an 
essential component of animal cell membranes and has mul-
tiple functions. We reasoned that incorporating cholesterol 
or cholesterol derivatives in the lipoplex formulation might 
increase the transfection efficiency and biocompatibility 
of the resulting SLNs. Previous studies have shown that 
lipid mixtures with cholesterol or cholesterol derivatives, 
which were generally synthesized using complicated proto-
cols, exhibited enhanced transfection.48–51 Cholesterol may 
improve transfection efficiency by promoting fusion of the 
lipoplex with the cell membrane.52 We decided to test cho-
lesteryl oleate because of its low melting point (44°C–47°C 
versus 148°C for cholesterol), which was compatible with 
our protocols.42 In this study, we have shown that cholesteryl 
oleate can be conveniently formulated in SLNs through a 
simple and uncomplicated protocol. The resulting vectors 
showed good performance in delivering DNA or siRNA 
into cells without cytotoxicity and with good transfection 
efficiency.
We compared in detail the properties of a series of 
SLNs with increasing quantities of cholesteryl oleate in its 
formulation. While all SLNs formed suspensions in aqueous 
media, the stability of the nanoparticles was decreased 
with high cholesteryl oleate concentrations (references 15 
and 16). Accordingly, electron microscopy studies revealed 
nearly spherical structures in those SLN formulations with 
low and intermediate concentrations of cholesteryl oleate 
and less spherical structures with abundant aggregation 
in those formulations with higher concentrations of cho-
lesteryl oleate. While the toxicity assessment results of 
the formulations containing any cholesteryl oleate con-
centration were similar to that observed for the control, 
the transfection efficiency of each compound differed 
according to the formulation. In the transient transfection 
experiments using firefly and Renilla luciferase expression 
vectors, reference 14 displayed robust, dose–response 
luciferase activation much higher than that observed 
for the other references. Therefore, this reference was 
selected for further studies using siRNA. Cytometry and 
confocal microscopy characterizations showed the ability 
of reference 14 to deliver siRNA molecules into cells. 
We observed massive and rapid uptake, as indicated by 
many large siRNA-labeled fluorescent dots throughout the 
cytoplasm at 1 h post-transfection, with a loss of signal at 
longer times post-transfection. Semiquantitative cytometry 
analysis showed approximately 45% cell incorporation, 
which is a remarkable transfection efficiency for a non-
functionalized nanoparticle-based delivery method.53 In 
addition to enhanced cellular uptake levels, siRNA delivery 
requires stabilization and protection against degradation 
by nucleases, which can impair the biological response. 
Targeting a chromosome-integrated luciferase gene, we 
observed an ~35% reduction in enzymatic activity, which 
demonstrates that upon SLN complexation, siRNA is 
protected against degradation, internalized by cells, and 
released intracellularly, ultimately leading to bioactiv-
ity. In this study, we used HEK293T and HeLa cells to 
establish experimental conditions for nucleic acid delivery 
into cells using SLNs formulated with cholesteryl oleate. 
Future experiments will test our formulation in hard-to-
transfect primary and cell lines to deliver nucleic acids to 
appropriate targets in order to interfere with relevant gene 
expression programs.
Conclusion
Nanoparticles can facilitate the intracellular delivery of 
siRNA, and many studies have shown that siRNA can 
have a significant therapeutic effect on disease, especially 
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has disadvantages in terms of transfection efficiency, immu-
nogenicity, and toxicity, all of which limit their therapeutic 
applications. The experiments reported in this study demon-
strate that the use of cholesteryl oleate in SLNs provides an 
avenue for the development of highly efficient and nontoxic 
delivery carriers for therapeutic applications.
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